-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Continuing Medical Education Grants Program
Novavax recognizes knowledge exchange as an important component of medical education and offers support for these programs through continuing medical education grants.
A continuing medical education grant is one in which Novavax provides funding for medical education activities or initiatives which serve to maintain, develop, or increase the knowledge, skills, and/or professional performance of a healthcare professional.
Grant funding may be available for activities, including live, print, enduring or web-based continuing medical education (CME) activities. Accredited CME activities are preferred.
Medical education grant requests are reviewed on a rolling basis. For questions about the medical education grants program or the request process, please contact Novavax at [email protected].
Areas of CME Interest
Novavax will consider unsolicited medical education grant requests related to:
- Increased understanding of the burden of COVID-19, influenza, and RSV disease in infants, children, adolescents, and adults
- Increased understanding of the immune response to COVID-19, influenza, and RSV vaccination in infants, children, adolescents, and adults
- Increased understanding of the prevention and treatment options for COVID-19, influenza, and RSV
- Increased awareness of ongoing research of preventative vaccines for COVID-19, influenza, and RSV
- Increased awareness and understanding of COVID-19 and influenza vaccination guidelines, including any gaps/limitations which may exist within current recommendation guidelines
- Addressing vaccine equity across all populations
- Addressing vaccine hesitancy
- Variations in dosing intervals and the mix-and-match approach for COVID-19 vaccines